Celgene's ($CELG) Otezla is the newest entrant in what is shaping up to be a summer throwdown among psoriasis drugmakers. Not surprisingly, every company's got its ...

Headache, upper respiratory infection, and nausea are some of Otezla’s more common side effects. As your body gets used to Otezla, some side effects may reduce or go away. This can take around 2 weeks ...

Otezla (apremilast) is an oral tablet commonly used to treat psoriatic arthritis in adults. Psoriatic arthritis is a long-lasting condition that affects the joints in people with psoriasis. Common ...

Odds are that anyone who has watched cable news of late has seen a commercial for Celgene ’s Otezla treatment for the skin condition psoriasis and psoriatic arthritis or one for its larger rival ...

Otezla (apremilast) is an oral tablet commonly used to treat plaque psoriasis in adults and children. Plaque psoriasis is an inflammatory skin condition that causes itchy, painful patches on the skin.

Celgene announced the release of new research findings on Otezla (apremilast), a selective inhibitor of phosphodiesterase 4 (PDE4), from the ESTEEM 1 and 2 Phase 3 studies in patients with moderate to ...

Otezla (apremilast) is a brand-name oral tablet that’s prescribed for conditions such as psoriatic arthritis. The drug’s cost with and without insurance can depend on several factors, such as whether ...

Celgene Corp. (NASDAQ: CELG) hit a biotech home run with Otezla, a fast-growing drug that's used to treat psoriatic arthritis and psoriasis. Since winning approval for use in psoriasis in September ...

Otezla (apremilast) and Humira (adalimumab) are prescription drugs used to treat plaque psoriasis and psoriatic arthritis in adults. Otezla comes as an oral tablet, and Humira comes as a liquid ...

THOUSAND OAKS, Calif., May 6, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced positive top-line results from the ADVANCE trial, a Phase 3, multicenter, randomized, placebo-controlled, ...

Sales of Otezla in 2018 were $1.6 billion driven by strong volume growth. Amgen has stated previously that it will focus on medicines that can deliver sustained, long-term volume driven growth and the ...